Overview

Non-Idiopathic Scoliosis Treated With Tranexamic Acid

Status:
Terminated

Trial end date:
2014-11-01

Target enrollment:
0

Participant gender:
All

Summary

Investigation of tranexamic acid (TXA) for reducing perioperative blood loss and transfusion requirement in pediatric patients with secondary scoliosis undergoing posterior spinal fusion.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

The Hospital for Sick Children

Treatments:

Tissue Plasminogen Activator
Tranexamic Acid

Criteria

Inclusion Criteria:

1. Children with secondary scoliosis undergoing posterior spinal fusion

Exclusion Criteria:

1. Known bleeding disorder as this may increase the risk of bleeding

2. Current antifibrinolytic therapy as these patients may bleed less

3. Patient or family history of thromboembolic disease as there may be potential risk of
thrombosis

4. Use of NSAIDS within 5 days of surgery as this may increase the risk of bleeding

5. Known allergy to TXA

6. History of renal insufficiency as TXA is renally excreted

7. Colour vision disturbance